Business Description
Vectus Biosystems Ltd
Compare
Compare
Traded in other countries / regions
VBS.Australia Description
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.21 | |||||
| Equity-to-Asset | -0.9 | |||||
| Debt-to-Equity | -1.7 | |||||
| Debt-to-EBITDA | -1.83 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 1 | |||||
| 3-Year EPS without NRI Growth Rate | -20.8 | |||||
| 3-Year FCF Growth Rate | -43.9 | |||||
| 3-Year Book Growth Rate | 15.4 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.29 | |||||
| 9-Day RSI | 40.09 | |||||
| 14-Day RSI | 39.49 | |||||
| 6-1 Month Momentum % | -3.55 | |||||
| 12-1 Month Momentum % | -41.58 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.5 | |||||
| Quick Ratio | 0.5 | |||||
| Cash Ratio | 0.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.8 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -86.93 | |||||
| ROIC % | -81.83 | |||||
| ROC (Joel Greenblatt) % | -710.91 | |||||
| ROCE % | -712.74 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -12.81 | |||||
| EV-to-EBITDA | -12.88 | |||||
| EV-to-FCF | -9.88 | |||||
| Earnings Yield (Greenblatt) % | -7.81 |
